Effects of aminophylline on respiratory drive and neuromuscular coupling in normal man and in patients with chronic airflow obstruction.
In order to evaluate the separate effects of aminophylline on the neural and muscular components of the respiratory control system, assessed by electromyographic activity of the diaphragm (EMGd) and mouth occlusion pressure (P0.1), respectively, 6 normal subjects and 14 patients with mild or moderate chronic airflow obstruction (8 asthmatics and 6 COPD) were studied during CO2 rebreathing, before and after administration of a therapeutic dose of aminophylline 5.6 mg/kg. Compared to normal subjects, before aminophylline administration both asthmatic and COPD patients exhibited a significantly greater value in EMGd response slope to CO2. In no group did aminophylline modify P0.1 or EMGd activity response slope to CO2, nor did it significantly affect neuromuscular coupling, assessed by plotting change in P0.1 against change in EMGd activity with increasing CO2. The data appear to indicate that aminophylline in therapeutic concentrations does not modify respiratory drive or neuromuscular coupling in normal subjects, or in patients with mild or moderate chronic airflow obstruction.
D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D000628:Aminophylline / Q000494:pharmacology*; D001249:Asthma / Q000503:physiopathology*; D002245:Carbon Dioxide / Q000378:metabolism; D004576:Electromyography; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000503:physiopathology*; D009469:Neuromuscular Junction / Q000187:drug effects*; D012119:Respiration / Q000187:drug effects*; D012129:Respiratory Function Tests
D002245:Carbon Dioxide; D000628:Aminophylline